A Phase 3 interventional study of WC3011 Estradiol Vaginal Cream and Vehicle in Vulvovaginal Atrophy, sponsored by Warner Chilcott. Completed at 57 sites in United States. Open to female participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2022-05-09.
Sponsored by Warner Chilcott (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Dyspareunia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Dyspareunia · United States.
Among the 56 studies in Dyspareunia with a site in United States, this one is the 4th largest by enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2013, is one of 13 in phase 3, and was the 12th registered.
159 studies on the registry are indexed under Dyspareunia; 40 are open to participants now.
Browse Dyspareunia studies →8 of the 56 studies in Dyspareunia with a site in United States are open now. Recruiting first, the newest first:
University of Arizona · Sites in United States
Ages 40–90 · Women only · Healthy volunteers
Azure Biotech Inc. · Sites in United States
Ages 45–60 · Women only
Medstar Health Research Institute · Sites in United States
Ages 18+ · Women only
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–50 · Women only
Indiana University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Dyspareunia studies recruiting now, 11 (39%) set no upper age limit and 14 (50%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 35 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 14 · Phase 4 8
First in 2004; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 550 is above the median of 64 across 127 interventional studies indexed under Dyspareunia.
Median enrollment 60 across the 53 interventional studies, 200 across the 3 observational. Of the 38 that completed or were terminated, 20 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 56 have an industry lead sponsor. The 10 most frequent:
This study is registered under Warner Chilcott, one of the names counted as AbbVie. Under that name alone:
Warner Chilcott is the lead sponsor of 58 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
AbbVie has 3 studies filed under Dyspareunia — fewer than ten, so there is no comparison to draw.
3 of the studies in Dyspareunia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06197568Azure Biotech Inc.Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women | 2026-12-31 |
| NCT05457972University Hospitals Cleveland Medical CenterPostpartum Vaginal Estrogen for Breastfeeding Patients | 2026-12-31 |
| NCT06059586Indiana UniversityPre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 56 studies in Dyspareunia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine if WC3011 is safe and effective in treating the symptom of painful intercourse secondary to vulvovaginal atrophy as measured by participant self-assessment when compared to vehicle.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vehicle applied to the vagina daily for 14 days followed by dosing 3 times per week for 10 weeks.
Drug: Vehicle
WC3011 Estradiol vaginal cream applied daily for 14 days followed by dosing 3 times per week for 10 weeks.
Drug: WC3011 Estradiol Vaginal Cream
Daily for 14 days followed by 3 times per week for 10 weeks
Also known as: WC3011
Daily for 14 days followed by 3 times per week for 10 weeks
Change From Baseline in Participant's Self-Assessment of Symptom of Vulvovaginal Atrophy (VVA): Dyspareunia (Pain Associated With Sexual Activity) to Final Assessment
Participant's self-assessment of the symptom of VVA (dyspareunia) was scored on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe. Higher score indicates the most bothersome symptoms. A negative change from Baseline indicates improvement. Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.
Time frame: Baseline (Day 0) to final assessment (Up to Week 12)
Change From Baseline in Vaginal pH to Final Assessment
Vaginal pH was obtained at baseline and final visit of the study. The pH was a numeric value from 0 to 14 expressing the acidity or alkalinity of the vaginal fluids where 7 was neutral, lower values were more acidic (values of 0-6) and higher values more alkaline (values of 8-14). A negative change from Baseline indicates improvement. Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.
Time frame: Baseline (Day 0) to final assessment (Up to Week 12)
Change From Baseline in the Percentage of Vaginal Superficial Cells to Final Assessment
Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of superficial cells. A positive change from Baseline indicates improvement. Final assessment is defined as the last available postbaseline assessment.
Time frame: Baseline (Day 0) to final assessment (Up to Week 12)
Change From Baseline in the Percentage of Vaginal Parabasal Cells to Final Assessment
Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of parabasal cells. A negative change from Baseline indicates improvement. Final assessment is defined as the last available postbaseline assessment.
Time frame: Baseline (Day 0) to final assessment (Up to Week 12)
Change From Baseline in Participant's Self-Assessment of the Symptom of VVA: Dyspareunia to Weeks 2, 4, 8, and 12
Participant's self-assessment of the symptom of VVA (dyspareunia) was scored on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe. Higher score indicates the most bothersome symptoms. A negative change from Baseline indicates improvement.
Time frame: Baseline to Weeks 2, 4, 8 and 12
Change From Baseline in Participant's Self-Assessment of the Other Symptoms of VVA to Weeks 2, 4, 8, 12, and Final Assessment
Self-Assessment of the symptoms of VVA, other than dyspareunia and vaginal bleeding associated with sexual activity, (vaginal and/or vulvar irritation/itching, dysuria and vaginal dryness) were evaluated by a questionnaire. Each symptom was scored on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe. Higher scores indicate the most bothersome symptoms. A negative change from Baseline indicates improvement. Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.
Time frame: Baseline (Day 0) to Weeks 2, 4, 8, 12, and final assessment (Up to Week 12)
Percentage of Participants With Vaginal Bleeding Associated With Sexual Activity at Each Visit
Vaginal bleeding associated with sexual activity was assessed by participants as either "present" or "absent". Number of participants with assessment "present" are reported. Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.
Time frame: Baseline (Day 0), Weeks 2, 4, 8, 12 and final assessment (Up to Week 12)
Change From Baseline in the Investigator's Assessment of Each of the Signs of VVA to Week 12 and Final Assessment
Investigator's assessment of vaginal health was performed by visual inspection of the vagina with respect to the signs of VVA: atrophy, pallor, vaginal dryness, friability, and petechiae each graded on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe. Higher scores are worse. A negative change from Baseline indicates improvement. Final assessment is defined as the last available postbaseline assessment.
Time frame: Baseline (Day 0) to Week 12 and Final assessment (Up to Week 12)
Change From Baseline in Vaginal pH to Week 12
Vaginal pH was obtained at baseline and final visit of the study. The pH was a numeric value from 0 to 14 expressing the acidity or alkalinity of the vaginal fluids where 7 was neutral, lower values were more acidic (values of 0-6) and higher values more alkaline (values of 8-14). A negative change from Baseline indicates improvement.
Time frame: Baseline to Week 12
Change From Baseline in the Percentage of Vaginal Superficial Cells to Week 12
Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of superficial cells. A positive change from Baseline indicates improvement.
Time frame: Baseline to Week 12
Change From Baseline in the Percentage of Vaginal Parabasal Cells to Week 12
Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of parabasal cells. A negative change from Baseline indicates improvement.
Time frame: Baseline to Week 12
| Milestone | Vehicle (3 Times/Week) | WC3011 Estradiol Vaginal Cream (3 Times/Week) |
|---|---|---|
| Started | 273 | 277 |
| Safety population | 271 | 277 |
| Modified intent-to-treat (mitt) population | 233 | 239 |
| Completed | 242 | 255 |
| Not completed | 31 | 22 |
| Withdrew: Adverse event | 7 | 10 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Withdrew consent | 12 | 4 |
| Withdrew: Protocol deviation | 7 | 4 |
| Withdrew: Reason not specified | 2 | 1 |
Participant's self-assessment of the symptom of VVA (dyspareunia) was scored on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe. Higher score indicates the most bothersome symptoms. A negative change from Baseline indicates improvement. Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.
| score on a scale | Vehicle (3 Times/Week) | WC3011 Estradiol Vaginal Cream (3 Times/Week) |
|---|---|---|
| Baseline | 2.7 ± 0.44 | 2.7 ± 0.45 |
| Change from Baseline to Final Assessment | -1.2 ± 0.93 | -1.5 ± 0.97 |
Vaginal pH was obtained at baseline and final visit of the study. The pH was a numeric value from 0 to 14 expressing the acidity or alkalinity of the vaginal fluids where 7 was neutral, lower values were more acidic (values of 0-6) and higher values more alkaline (values of 8-14). A negative change from Baseline indicates improvement. Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.
| score on a scale | Vehicle (3 Times/Week) | WC3011 Estradiol Vaginal Cream (3 Times/Week) |
|---|---|---|
| Baseline | 6.35 ± 0.66 | 6.37 ± 0.66 |
| Change from Baseline to Final Assessment | -0.53 ± 0.92 | -1.36 ± 0.89 |
Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of superficial cells. A positive change from Baseline indicates improvement. Final assessment is defined as the last available postbaseline assessment.
| percentage of superficial cells | Vehicle (3 Times/Week) | WC3011 Estradiol Vaginal Cream (3 Times/Week) |
|---|---|---|
| Baseline | 0.2 ± 0.75 | 0.2 ± 0.70 |
| Change from Baseline to Final Assessment | 1.4 ± 6.08 | 10.1 ± 16.72 |
Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of parabasal cells. A negative change from Baseline indicates improvement. Final assessment is defined as the last available postbaseline assessment.
| percentage of parabasal cells | Vehicle (3 Times/Week) | WC3011 Estradiol Vaginal Cream (3 Times/Week) |
|---|---|---|
| Baseline | 50.6 ± 43.09 | 53.5 ± 42.00 |
| Change From Baseline to Final Assessment | -14.6 ± 39.55 | -48.5 ± 45.11 |
Participant's self-assessment of the symptom of VVA (dyspareunia) was scored on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe. Higher score indicates the most bothersome symptoms. A negative change from Baseline indicates improvement.
| score on a scale | Vehicle (3 Times/Week) | WC3011 Estradiol Vaginal Cream (3 Times/Week) |
|---|---|---|
| Baseline | 2.7 ± 0.44 | 2.7 ± 0.45 |
| Change From Baseline to Week 2 | -0.8 ± 0.87 | -0.8 ± 0.89 |
| Change From Baseline to Week 4 | -1.1 ± 0.93 | -1.2 ± 0.93 |
| Change From Baseline to Week 8 | -1.2 ± 0.92 | -1.5 ± 0.96 |
| Change From Baseline to Week 12 | -1.2 ± 0.90 | -1.5 ± 0.95 |
Self-Assessment of the symptoms of VVA, other than dyspareunia and vaginal bleeding associated with sexual activity, (vaginal and/or vulvar irritation/itching, dysuria and vaginal dryness) were evaluated by a questionnaire. Each symptom was scored on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe. Higher scores indicate the most bothersome symptoms. A negative change from Baseline indicates improvement. Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.
| score on a scale | Vehicle (3 Times/Week) | WC3011 Estradiol Vaginal Cream (3 Times/Week) |
|---|---|---|
| Vaginal Itching-Baseline | 0.9 ± 0.89 | 1.0 ± 0.89 |
| Vaginal Itching-Change From Baseline to Week 2 | -0.3 ± 0.94 | -0.3 ± 0.94 |
| Vaginal Itching-Change From Baseline to Week 4 | -0.5 ± 0.94 | -0.3 ± 0.96 |
| Vaginal Itching-Change From Baseline to Week 8 | -0.5 ± 0.98 | -0.4 ± 0.97 |
| Vaginal Itching-Change From Baseline to Week 12 | -0.6 ± 0.95 | -0.4 ± 0.96 |
| Vaginal Itching-Change From Baseline to Final Assessment | -0.5 ± 0.98 | -0.4 ± 0.95 |
| Dysuria-Baseline | 0.4 ± 0.74 | 0.4 ± 0.72 |
| Dysuria-Change From Baseline to Week 2 | -0.1 ± 0.82 | -0.1 ± 0.77 |
| Dysuria-Change From Baseline to Week 4 | -0.2 ± 0.76 | -0.1 ± 0.80 |
| Dysuria-Change From Baseline to Week 8 | -0.2 ± 0.73 | -0.2 ± 0.76 |
| Dysuria-Change From Baseline to Week 12 | -0.2 ± 0.78 | -0.2 ± 0.75 |
| Dysuria-Change From Baseline to Final Assessment | -0.2 ± 0.80 | -0.2 ± 0.72 |
| Vaginal Dryness-Baseline | 2.3 ± 0.80 | 2.3 ± 0.73 |
| Vaginal Dryness-Change From Baseline to Week 2 | -0.6 ± 1.08 | -0.7 ± 1.00 |
| Vaginal Dryness-Change From Baseline to Week 4 | -0.8 ± 0.96 | -0.9 ± 0.91 |
| Vaginal Dryness-Change From Baseline to Week 8 | -0.9 ± 0.98 | -1.1 ± 0.91 |
| Vaginal Dryness-Change From Baseline to Week 12 | -0.9 ± 0.98 | -1.2 ± 0.94 |
| Vaginal Dryness-Change From Baseline to Final Assessment | -0.8 ± 0.98 | -1.2 ± 0.97 |
Vaginal bleeding associated with sexual activity was assessed by participants as either "present" or "absent". Number of participants with assessment "present" are reported. Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.
| percentage of participants | Vehicle (3 Times/Week) | WC3011 Estradiol Vaginal Cream (3 Times/Week) |
|---|---|---|
| Baseline | 27.0 | 28.0 |
| Week 2 | 15.9 | 16.4 |
| Week 4 | 7.9 | 7.2 |
| Week 8 | 10.8 | 6.7 |
| Week 12 | 12.1 | 7.5 |
| Final Assessment | 14.4 | 6.5 |
Investigator's assessment of vaginal health was performed by visual inspection of the vagina with respect to the signs of VVA: atrophy, pallor, vaginal dryness, friability, and petechiae each graded on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe. Higher scores are worse. A negative change from Baseline indicates improvement. Final assessment is defined as the last available postbaseline assessment.
| score on a scale | Vehicle (3 Times/Week) | WC3011 Estradiol Vaginal Cream (3 Times/Week) |
|---|---|---|
| Atrophy-Baseline | 2.0 ± 0.60 | 2.0 ± 0.64 |
| Atrophy-Change From Baseline to Week 12 | -0.5 ± 0.75 | -0.9 ± 0.84 |
| Atrophy-Change From Baseline to Final Assessment | -0.5 ± 0.75 | -0.9 ± 0.83 |
| Pallor-Baseline | 1.8 ± 0.69 | 1.8 ± 0.70 |
| Pallor-Change From Baseline to Week 12 | -0.6 ± 0.75 | -0.9 ± 0.84 |
| Pallor-Change From Baseline to Final Assessment | -0.6 ± 0.75 | -0.9 ± 0.85 |
| Dryness-Baseline | 1.8 ± 0.68 | 1.8 ± 0.75 |
| Dryness-Change From Baseline to Week 12 | -0.5 ± 0.85 | -0.9 ± 0.94 |
| Dryness-Change From Baseline to Final Assessment | -0.5 ± 0.83 | -0.9 ± 0.95 |
| Friability-Baseline | 1.1 ± 0.93 | 1.2 ± 0.99 |
| Friability-Change From Baseline to Week 12 | -0.6 ± 0.95 | -1.0 ± 0.99 |
| Friability-Change From Baseline to Final Assessment | -0.6 ± 0.95 | -1.0 ± 0.97 |
| Petechiae-Baseline | 0.7 ± 0.83 | 0.8 ± 0.89 |
| Petechiae-Change From Baseline to Week 12 | -0.3 ± 0.78 | -0.6 ± 0.86 |
| Petechiae-Change From Baseline to Final Assessment | -0.3 ± 0.78 | -0.6 ± 0.85 |
Vaginal pH was obtained at baseline and final visit of the study. The pH was a numeric value from 0 to 14 expressing the acidity or alkalinity of the vaginal fluids where 7 was neutral, lower values were more acidic (values of 0-6) and higher values more alkaline (values of 8-14). A negative change from Baseline indicates improvement.
| score on a scale | Vehicle (3 Times/Week) | WC3011 Estradiol Vaginal Cream (3 Times/Week) |
|---|---|---|
| Baseline | 6.35 ± 0.66 | 6.37 ± 0.66 |
| Change From Baseline to Week 12 | -0.53 ± 0.93 | -1.35 ± 0.89 |
Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of superficial cells. A positive change from Baseline indicates improvement.
| percentage of superficial cells | Vehicle (3 Times/Week) | WC3011 Estradiol Vaginal Cream (3 Times/Week) |
|---|---|---|
| Baseline | 0.2 ± 0.75 | 0.2 ± 0.70 |
| Change From Baseline to Week 12 | 1.2 ± 5.35 | 10.5 ± 17.19 |
Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of parabasal cells. A negative change from Baseline indicates improvement.
| percentage of parabasal cells | Vehicle (3 Times/Week) | WC3011 Estradiol Vaginal Cream (3 Times/Week) |
|---|---|---|
| Baseline | 50.6 ± 43.09 | 53.5 ± 42.00 |
| Change From Baseline to Week 12 | -14.9 ± 39.88 | -48.2 ± 45.65 |
Collected over Up to Week 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vehicle (3 Times/Week) | 0/271 (0%) | 1/271 (0.4%) | 42/271 (15.5%) |
| WC3011 Estradiol Vaginal Cream (3 Times/Week) | 0/277 (0%) | 3/277 (1.1%) | 38/277 (13.7%) |
| Event | Vehicle (3 Times/Week) | WC3011 Estradiol Vaginal Cream (3 Times/Week) |
|---|---|---|
| Atrial FibrillationCardiac disorders | 1/271 | 0/277 |
| AppendicitisInfections and infestations | 0/271 | 1/277 |
| Accidental OverdoseInjury, poisoning and procedural complications | 0/271 | 1/277 |
| Brain NeoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/271 | 1/277 |
| Deep vein thrombosisVascular disorders | 0/271 | 1/277 |
| Event | Vehicle (3 Times/Week) | WC3011 Estradiol Vaginal Cream (3 Times/Week) |
|---|---|---|
| Urinary tract infectionInfections and infestations | 21/271 | 10/277 |
| Vulvovaginal mycotic infectionInfections and infestations | 9/271 | 19/277 |
| Application site painGeneral disorders | 15/271 | 9/277 |
Safety Population included participants who were randomized into the study and took at least 1 dose of study drug.
| Age, Continuous(years) | Vehicle (3 Times/Week) | WC3011 Estradiol Vaginal Cream (3 Times/Week) | Total |
|---|---|---|---|
| Mean | 58.6 ± 6.1 | 58.7 ± 6.4 | 58.6 ± 6.3 |
| Sex: Female, Male(Participants) | Vehicle (3 Times/Week) | WC3011 Estradiol Vaginal Cream (3 Times/Week) | Total |
|---|---|---|---|
| Female | 271 | 277 | 548 |
| Male | 0 | 0 | 0 |
Ran from Apr 2013 to primary completion in Nov 2013, 7 months.
Results were first posted in May 2022, 8 years 5 months after primary completion. A results delay was requested in Feb 2015.
Of 10 phase 3 interventional studies under Dyspareunia, half reached primary completion within 13 months of starting (the median); a quarter within 5 and three quarters within 28. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Estradiol